Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial von Motzer, Robert J, Rini, Brian I, McDermott, David F, Redman, Bruce G, Kuzel, Timothy M, Harrison, Michael R, Vaishampayan, Ulka N, Drabkin, Harry A, George, Saby, Logan, Theodore F, Margolin, Kim A, Plimack, Elizabeth R, Lambert, Alexandre M, Waxman, Ian M, Hammers, Hans J

Volltext

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advance... von Chesney, Jason, Puzanov, Igor, Collichio, Frances, Singh, Parminder, Milhem, Mohammed M, Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore F, Hauschild, Axel, Lebbé, Celeste, Chen, Lisa, Kim, Jenny J, Gansert, Jennifer, Andtbacka, Robert H I, Kaufman, Howard L

Volltext

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial von Weber, Jeffrey S, Prof, Gibney, Geoff, MD, Sullivan, Ryan J, MD, Sosman, Jeffrey A, Prof, Slingluff, Craig L, Prof, Lawrence, Donald P, MD, Logan, Theodore F, MD, Schuchter, Lynn M, Prof, Nair, Suresh, MD, Fecher, Leslie, MD, Buchbinder, Elizabeth I, MD, Berghorn, Elmer, BSN, Ruisi, Mary, MD, Kong, George, PhD, Jiang, Joel, PhD, Horak, Christine, PhD, Hodi, F Stephen, Dr

Volltext

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial von Margolin, Kim, Prof, Ernstoff, Marc S, MD, Hamid, Omid, MD, Lawrence, Donald, MD, McDermott, David, MD, Puzanov, Igor, MD, Wolchok, Jedd D, MD, Clark, Joseph I, Prof, Sznol, Mario, MD, Logan, Theodore F, MD, Richards, Jon, MD, Michener, Tracy, PharmD, Balogh, Agnes, MS, Heller, Kevin N, MD, Hodi, F Stephen, MD

Volltext

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial von Armstrong, Andrew J, Dr, Halabi, Susan, Prof, Eisen, Tim, Prof, Broderick, Samuel, MS, Stadler, Walter M, Prof, Jones, Robert J, Prof, Garcia, Jorge A, MD, Vaishampayan, Ulka N, Prof, Picus, Joel, Prof, Hawkins, Robert E, Prof, Hainsworth, John D, Prof, Kollmannsberger, Christian K, Prof, Logan, Theodore F, Prof, Puzanov, Igor, MD, Pickering, Lisa M, MD, Ryan, Christopher W, MD, Protheroe, Andrew, MD, Lusk, Christine M, MPH, Oberg, Sadie, BS, George, Daniel J, Prof

Volltext

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 von Atkins, Michael B, Lee, Sandra J, Chmielowski, Bartosz, Tarhini, Ahmad A, Cohen, Gary I, Truong, Thach-Giao, Moon, Helen H, Davar, Diwakar, O'Rourke, Mark, Stephenson, Joseph J, Curti, Brendan D, Urba, Walter J, Brell, Joanna M, Funchain, Pauline, Kendra, Kari L, Ikeguchi, Alexandra P, Jaslowski, Anthony, Bane, Charles L, Taylor, Mark A, Bajaj, Madhuri, Conry, Robert M, Ellis, Robert J, Logan, Theodore F, Laudi, Noel, Sosman, Jeffrey A, Crockett, David G, Pecora, Andrew L, Okazaki, Ian J, Reganti, Sowjanya, Chandra, Sunandana, Guild, Samantha, Chen, Helen X, Streicher, Howard Z, Wolchok, Jedd D, Ribas, Antoni, Kirkwood, John M

Volltext

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody von Segal, Neil H, Logan, Theodore F, Hodi, F Stephen, McDermott, David, Melero, Ignacio, Hamid, Omid, Schmidt, Henrik, Robert, Caroline, Chiarion-Sileni, Vanna, Ascierto, Paolo A, Maio, Michele, Urba, Walter J, Gangadhar, Tara C, Suryawanshi, Satyendra, Neely, Jaclyn, Jure-Kunkel, Maria, Krishnan, Suba, Kohrt, Holbrook, Sznol, Mario, Levy, Ronald

Volltext

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma von CHOUEIRI, Toni K, VAISHAMPAYAN, Ulka, OTTESEN, Lone H, LAUBSCHER, Kevin H, SHERMAN, Laurie, MCDERMOTT, David F, HAAS, Naomi B, FLAHERTY, Keith T, ROSS, Robert, EISENBERG, Peter, MELTZER, Paul S, MERINO, Maria J, ROSENBERG, Jonathan E, BOTTARO, Donald P, MARSTON LINEHAN, W, SRINIVASAN, Ramaprasad, LOGAN, Theodore F, HARZSTARK, Andrea L, BUKOWSKI, Ronald M, RINI, Brian I, SRINIVAS, Sandy, STEIN, Mark N, ADAMS, Laurel M

Volltext

CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus von Zlotoff, Daniel A., Sambandam, Arivazhagan, Logan, Theodore D., Bell, J. Jeremiah, Schwarz, Benjamin A., Bhandoola, Avinash

Volltext

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003 von Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.

Volltext

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus von Maroto, Jose Pablo, Hudes, Gary, Dutcher, Janice P, Logan, Theodore F, White, Charles S, Krygowski, Mizue, Cincotta, Maria, Shapiro, Mark, Duran, Ignacio, Berkenblit, Anna

Volltext

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma von ATKINS, Michael B, HIDALGO, Manuel, DUKART, Gary, SHERMAN, Matthew L, STADLER, Walter M, LOGAN, Theodore F, DUTCHER, Janice P, HUDES, Gary R, PARK, Young, LIOU, Song-Heng, MARSHALL, Bonnie, BONI, Joseph P

Volltext

Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer von Logan, Theodore F.

Volltext

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma von McDermott, David F, Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A, Clark, Joseph I, Sosman, Jeffrey A, Dutcher, Janice P, Logan, Theodore F, Curti, Brendan D, Ernstoff, Marc S, Appleman, Leonard, Wong, Michael K K, Khushalani, Nikhil I, Oleksowicz, Leslie, Vaishampayan, Ulka N, Mier, James W, Panka, David J, Bhatt, Rupal S, Bailey, Alexandra S, Leibovich, Bradley C, Kwon, Eugene D, Kabbinavar, Fairooz F, Belldegrun, Arie S, Figlin, Robert A, Pantuck, Allan J, Regan, Meredith M, Atkins, Michael B

Volltext

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma von McDermott, David F, Regan, Meredith M, Clark, Joseph I, Flaherty, Lawrence E, Weiss, Geoffery R, Logan, Theodore F, Kirkwood, John M, Gordon, Michael S, Sosman, Jeffrey A, Ernstoff, Marc S, Tretter, Christopher P G, Urba, Walter J, Smith, John W, Margolin, Kim A, Mier, James W, Gollob, Jared A, Dutcher, Janice P, Atkins, Michael B

Volltext

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma von Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.

Volltext

Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma von Armstrong, Andrew J., Nixon, Andrew B., Carmack, Andrea, Yang, Qian, Eisen, Tim, Stadler, Walter M., Jones, Robert J., Garcia, Jorge A., Vaishampayan, Ulka N., Picus, Joel, Hawkins, Robert E., Hainsworth, John D., Kollmannsberger, Christian K., Logan, Theodore F., Puzanov, Igor, Pickering, Lisa M., Ryan, Christopher W., Protheroe, Andrew, George, Daniel J., Halabi, Susan

Volltext

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma von Voss, Martin H., Bhatt, Rupal S., Vogelzang, Nicholas J., Fishman, Mayer, Alter, Robert S., Rini, Brian I., Beck, J. Thaddeus, Joshi, Monika, Hauke, Ralph, Atkins, Michael B., Burgess, Earle, Logan, Theodore F., Shaffer, David, Parikh, Rahul, Moazzam, Nauman, Zhang, Xiaosha, Glasser, Chad, Sherman, Matthew L., Plimack, Elizabeth R.

Volltext

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy von Bradish, Joshua R, Richey, Justin D, Post, Kristin M, Meehan, Kari, Sen, Joyashree D, Malek, Amanda J, Katona, Terrence M, Warren, Simon, Logan, Theodore F, Fecher, Leslie A, Cheng, Liang

Volltext

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase... von Amin, Asim, Dudek, Arkadiusz Z, Logan, Theodore F, Lance, Raymond S, Holzbeierlein, Jeffrey M, Knox, Jennifer J, Master, Viraj A, Pal, Sumanta K, Miller, Jr, Wilson H, Karsh, Lawrence I, Tcherepanova, Irina Y, DeBenedette, Mark A, Williams, W Lee, Plessinger, Douglas C, Nicolette, Charles A, Figlin, Robert A

Volltext